Interim Management Statement

News Release

19 March 2014

Consort Medical plc

Interim Management Statement

Consort Medical plc ("Consort Medical") (LSE: CSRT), today issues its Interim Management Statement for the period from 1 November 2013 to date.

Consort Medical is trading well, in line with the Board's expectations.

In February we announced that Bespak's INJ300 development programme had received regulatory approval from the FDA. We are delighted to confirm that Dr. Reddy's Laboratories launched the product at the end of February. INJ300 is an autoinjector for Sumatriptan, a migraine therapy. This is the first Bespak autoinjector programme to receive regulatory approval and product launch.

Jonathan Glenn, Consort Medical's Chief Executive commented: "The launch of our first autoinjector represents a major milestone for Consort Medical's Injectables technology, confirms Bespak's capability in the autoinjector market, and is a significant step in the execution of our diversification strategy."

Consort Medical's consolidated financial position remains strong, with net cash at 28 February 2014 of £30.5 million.

Consort Medical's Preliminary Results will be released on Tuesday 17 June 2014.

-Ends-

Enquiries:

Consort Medical plc is an international medical devices company, focused on developing and manufacturing disposable medical devices for drug delivery. The principal business of the Company is the management of Bespak, a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

The Group has facilities in King's Lynn, Cambridge, Nelson, Milton Keynes and Hemel Hempstead in the UK. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT). The Group's website address is www.consortmedical.com.